Nothing changes for drug patents regardless of whether an LLM was used in the discovery process.
Not sure why this should be true; the US Supreme Court recently chose to let precedent stand that AI creations are not copyrightable. https://www.reuters.com/legal/government/us-supreme-court-de...
That also seems relevant for this whole discussion, actually -- if a work can't be copyrighted it certainly can't have a changed license, or any license at all. (I guess it's effectively public domain to the extent that it's public at all?)
Even if all I have to do is tell my agent, "here is a patent for a drug, analyse the patent and determine an equivalent but non-infringing drug" and it chugs away for a couple of hours and spits out a drug along with all the specifications to manufacture it?
I guess the state of play will be that for new drugs the original manufacturer will already have done that and ensured that literally anything that could be found as a workaround is included in the scope of the patent. But I feel like it will not be possible to keep that wartertight.